MY138165A - Use of substituted cyclopropane acid derivatives for producing medicaments for treating the metabolic syndrome - Google Patents
Use of substituted cyclopropane acid derivatives for producing medicaments for treating the metabolic syndromeInfo
- Publication number
- MY138165A MY138165A MYPI20055838A MYPI20055838A MY138165A MY 138165 A MY138165 A MY 138165A MY PI20055838 A MYPI20055838 A MY PI20055838A MY PI20055838 A MYPI20055838 A MY PI20055838A MY 138165 A MY138165 A MY 138165A
- Authority
- MY
- Malaysia
- Prior art keywords
- acid derivatives
- metabolic syndrome
- treating
- substituted cyclopropane
- producing medicaments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING MEDICAMENTS FOR TREATING THE ME7ABOLIC SYNDROME 5 THE INVENTION RELATES TO THE USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES AND OF THEIR PHYSIOLOGICALLY TOLERATED SAILS I-OR PRODUCING MEDICAMENTS FOR THE (REATINENT OFTHE METABOLIC SYNDROME. 10 THE USE OF THE COMPOUNDS OF THE FOLINULA I 0 0 R1,, 0 " 0 @R2 R6 R3 R5 R4- I IN WHICH THE RADICALS HAVE THE STATED MEANINGS, AND OFTHE PHYSIOLOGICALLY TOLERATED SALTS I THEREOF FOR PRODUCING A MEDICAMENT FOR THE TREATMENT OF THE METABOLIC SYNDROME IS 15 DESCRIBED.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004060041A DE102004060041A1 (en) | 2004-12-14 | 2004-12-14 | Use of substituted cyclopropane acid derivative having dopamine receptor ligand activity to e.g. treat metabolic syndrome; reduce lipid in the plasma; lower free fatty acid in the plasma; and treat diabetic dyslipidemia |
DE102005039245 | 2005-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MY138165A true MY138165A (en) | 2009-04-30 |
Family
ID=35945136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI20055838A MY138165A (en) | 2004-12-14 | 2005-12-13 | Use of substituted cyclopropane acid derivatives for producing medicaments for treating the metabolic syndrome |
Country Status (20)
Country | Link |
---|---|
US (2) | US20080045590A1 (en) |
EP (1) | EP1827415B1 (en) |
JP (1) | JP2008523122A (en) |
KR (1) | KR20070086194A (en) |
AR (1) | AR052265A1 (en) |
AT (1) | ATE455543T1 (en) |
AU (1) | AU2005315975A1 (en) |
BR (1) | BRPI0519064A2 (en) |
CA (1) | CA2590024A1 (en) |
DE (1) | DE502005008929D1 (en) |
IL (1) | IL183464A0 (en) |
MA (1) | MA29131B1 (en) |
MX (1) | MX2007006798A (en) |
MY (1) | MY138165A (en) |
NO (1) | NO20073031L (en) |
NZ (1) | NZ555155A (en) |
RU (1) | RU2007126842A (en) |
TW (1) | TW200635575A (en) |
UY (1) | UY29256A1 (en) |
WO (1) | WO2006063681A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8053867B2 (en) * | 2008-08-20 | 2011-11-08 | Honeywell International Inc. | Phosphorous-comprising dopants and methods for forming phosphorous-doped regions in semiconductor substrates using phosphorous-comprising dopants |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4497815B2 (en) * | 2001-02-16 | 2010-07-07 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands |
WO2003053352A2 (en) * | 2001-12-20 | 2003-07-03 | Merck & Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
PE20030701A1 (en) * | 2001-12-20 | 2003-08-21 | Schering Corp | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS |
-
2005
- 2005-11-30 MX MX2007006798A patent/MX2007006798A/en not_active Application Discontinuation
- 2005-11-30 BR BRPI0519064-9A patent/BRPI0519064A2/en not_active IP Right Cessation
- 2005-11-30 AU AU2005315975A patent/AU2005315975A1/en not_active Abandoned
- 2005-11-30 AT AT05814551T patent/ATE455543T1/en not_active IP Right Cessation
- 2005-11-30 CA CA002590024A patent/CA2590024A1/en not_active Abandoned
- 2005-11-30 NZ NZ555155A patent/NZ555155A/en not_active IP Right Cessation
- 2005-11-30 JP JP2007545874A patent/JP2008523122A/en not_active Abandoned
- 2005-11-30 DE DE502005008929T patent/DE502005008929D1/en active Active
- 2005-11-30 EP EP05814551A patent/EP1827415B1/en active Active
- 2005-11-30 KR KR1020077013437A patent/KR20070086194A/en not_active Application Discontinuation
- 2005-11-30 WO PCT/EP2005/012763 patent/WO2006063681A1/en active Application Filing
- 2005-11-30 RU RU2007126842/15A patent/RU2007126842A/en not_active Application Discontinuation
- 2005-12-12 AR ARP050105191A patent/AR052265A1/en not_active Application Discontinuation
- 2005-12-12 TW TW094143771A patent/TW200635575A/en unknown
- 2005-12-13 MY MYPI20055838A patent/MY138165A/en unknown
- 2005-12-20 UY UY29256A patent/UY29256A1/en unknown
-
2007
- 2007-05-28 IL IL183464A patent/IL183464A0/en unknown
- 2007-06-07 US US11/759,510 patent/US20080045590A1/en not_active Abandoned
- 2007-06-12 MA MA29989A patent/MA29131B1/en unknown
- 2007-06-14 NO NO20073031A patent/NO20073031L/en not_active Application Discontinuation
-
2008
- 2008-12-04 US US12/328,052 patent/US8222240B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2007006798A (en) | 2007-08-07 |
JP2008523122A (en) | 2008-07-03 |
EP1827415A1 (en) | 2007-09-05 |
IL183464A0 (en) | 2007-10-31 |
NO20073031L (en) | 2007-08-03 |
US20080045590A1 (en) | 2008-02-21 |
WO2006063681A1 (en) | 2006-06-22 |
EP1827415B1 (en) | 2010-01-20 |
AU2005315975A1 (en) | 2006-06-22 |
DE502005008929D1 (en) | 2010-03-11 |
KR20070086194A (en) | 2007-08-27 |
NZ555155A (en) | 2009-09-25 |
CA2590024A1 (en) | 2006-06-22 |
US8222240B2 (en) | 2012-07-17 |
RU2007126842A (en) | 2009-01-27 |
US20090088474A1 (en) | 2009-04-02 |
AR052265A1 (en) | 2007-03-07 |
TW200635575A (en) | 2006-10-16 |
BRPI0519064A2 (en) | 2008-12-23 |
ATE455543T1 (en) | 2010-02-15 |
UY29256A1 (en) | 2006-07-31 |
MA29131B1 (en) | 2008-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009006742A (en) | Novel compounds. | |
HK1091121A1 (en) | Substituted 2-aminotetralins for the treatment of depressions | |
IL173203A0 (en) | Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament | |
MX2009008228A (en) | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase. | |
WO2008101907A3 (en) | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase | |
SE0202462D0 (en) | Novel use | |
TW200635582A (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
PT1147110E (en) | PIRAZINE (AZA) -INDOL DERIVATIVES | |
UA85708C2 (en) | Benzoxazine-containing pharmaceutical combinations for treating respiratory tract diseases | |
SG148177A1 (en) | Novel cis-imidazolines | |
DE50311898D1 (en) | FREDERICAMYCIN DERIVATIVES AS A MEDICAMENT FOR TUMOR TREATMENT | |
UA74346C2 (en) | Aminodicarboxylic acids derivatives, use thereof and a medicament | |
EA201001669A1 (en) | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | |
UA86977C2 (en) | Hydantoin derivatives for the treatment of obstructive airway diseases | |
EP2039686A4 (en) | Dihydropyrimidine compounds and their uses in preparation of medicaments for treating and preventing antiviral diseases | |
TW200604196A (en) | New quinuclidine derivatives and pharmaceutical compositions comprising them | |
MXPA06013221A (en) | Inhalation powder formulations containing enantiomerically pure beta-agonists. | |
UA85707C2 (en) | Benzoxazines for treating respiratory tract diseases | |
SE0401342D0 (en) | Therapeutic compounds | |
MX2009006913A (en) | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome. | |
TW200637544A (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
MY148955A (en) | Carbamoly-cyclohexanes for treating acute mania | |
TW200510352A (en) | Cycloalkyl substituted amino acid derivatives, processes for their freparation and their use as pharmaceuticals | |
ATE311866T1 (en) | USE OF R-ARYLPROPIONIC ACIDS FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF DISEASES OF A RHEUMATIC NATURE | |
DE602007014193D1 (en) | TREATMENT OF PSYCHIATRIC PATIENTS WITH SLEEP DISORDERS AND / OR EXCESSIVE TAGESSLESSNESS WITH PALIPERIDONE |